HPSE

HPSE (heparanase) is an endo-glucuronidase whose cleavage of heparan sulfate chains on extracellular matrix proteoglycans liberates ECM-sequestered factors and drives invasion, angiogenesis, and tissue remodeling (PMID:27347307). In the lung, HMGB1 signaling through RAGE activates NF-κB, which binds the HPSE promoter to induce transcription; the resulting heparanase cleaves heparan sulfate on myofibroblast ECM to release latent TGF-β and promote bronchiolitis obliterans syndrome (PMID:27347307). Beyond matrix degradation, HPSE acts as an upstream driver of tumor cell adhesion, migration, and invasion by upregulating the chemokines IL-8 and CXCL1 in a manner correlated with p38, JNK, and ERK1/2 MAPK activation (PMID:22719918), and its expression is post-transcriptionally restrained by miR-503-3p, an axis through which suppression of HPSE inhibits osteoclast differentiation (PMID:34592492). Lower-confidence findings additionally link HPSE to autophagy-associated chemotherapy resistance (PMID:26571129) and to early corneal neovascularization (PMID:20958185).

1. 2009 Low

   Addressed whether HPSE expression is genetically controlled, finding common SNPs that regulate heparanase at multiple levels and revealing a disconnect between mRNA and circulating protein.

   Evidence SNP genotyping with haplotype analysis, RT-PCR and plasma ELISA in a healthy cohort

   PMID:19406828

   Open questions at the time

   • Association only, no direct functional manipulation
   • Mechanism of the inverse mRNA/protein correlation (secretion vs translation) unresolved
   • Single small population cohort
2. 2010 Low

   Tested whether HPSE acts before angiogenesis, showing it appears prior to vessel ingrowth across diverse corneal injury models and positioning it as a pioneer factor for neovascularization.

   Evidence Immunohistochemistry and double immunofluorescence with temporal analysis in five mouse corneal neovascularization models

   PMID:20958185

   Open questions at the time

   • Correlative localization without HPSE loss/gain of function
   • Does not establish causality for vessel growth
   • Mechanism linking HPSE to endothelial recruitment unaddressed
3. 2012 Medium

   Placed HPSE upstream of chemokine-driven invasion, showing it controls IL-8 and CXCL1 expression in correlation with MAPK signaling rather than acting solely through matrix degradation.

   Evidence Artificial miRNA knockdown with rescue, in vitro invasion/migration and xenograft assays, MAPK phosphorylation Western blot in melanoma cells

   PMID:22719918

   Open questions at the time

   • Causal link between MAPK activation and chemokine induction is correlative
   • Whether enzymatic activity is required for chemokine regulation not resolved
   • Single cancer cell type
4. 2015 Low

   Proposed a non-canonical, intracellular role for HPSE in modulating autophagy to confer growth advantage and chemoresistance, distinct from its ECM-degrading function.

   Evidence Cell-based autophagy assays with HPSE gain/loss of function in normal and cancer cell lines

   PMID:26571129

   Open questions at the time

   • Methodological detail limited to summary-level
   • Molecular mechanism connecting HPSE to autophagy machinery undefined
   • Not independently confirmed
5. 2016 Medium

   Dissected the transcriptional circuit driving HPSE in tissue remodeling, establishing the HMGB1/RAGE/NF-κB axis as inducer and latent TGF-β release as a key downstream consequence.

   Evidence Mouse tracheal transplant BOS model with HMGB1 blockade and HPSE inhibition, NF-κB promoter binding assay, TGF-β release assay

   PMID:27347307

   Open questions at the time

   • Direct NF-κB occupancy of the HPSE promoter shown by binding assay but not by genetic dissection of the site
   • Generalizability beyond the BOS model untested
   • Single lab
6. 2021 Medium

   Identified a post-transcriptional brake on HPSE, showing osteoblast exosome-delivered miR-503-3p directly targets HPSE mRNA to suppress osteoclast differentiation.

   Evidence Exosome isolation, miRNA target validation, miR-503-3p and Hpse gain/loss of function, osteoclast differentiation assays

   PMID:34592492

   Open questions at the time

   • Whether HPSE enzymatic activity drives osteoclastogenesis not addressed
   • Direct miR-503-3p binding to HPSE 3'UTR confirmation context limited
   • Single lab

• How HPSE's enzymatic heparan sulfate cleavage is mechanistically coupled to its intracellular signaling roles (MAPK/chemokine induction, autophagy) remains unresolved.
• No structural or catalytic dissection distinguishing enzymatic vs non-enzymatic functions in the corpus
• Direct substrates beyond ECM heparan sulfate not enumerated
• Mechanism linking HS cleavage to signaling output undefined